GeneDx Holdings Corp.
WGS
$85.74
-$5.87-6.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 52.07% | 54.43% | 31.73% | 3.66% | -0.82% |
| Total Other Revenue | -52.01% | -52.36% | -39.62% | -16.37% | -3.64% |
| Total Revenue | 48.81% | 50.79% | 29.41% | 3.06% | -0.91% |
| Cost of Revenue | 3.71% | -2.15% | -34.14% | -46.84% | -53.76% |
| Gross Profit | 93.63% | 118.16% | 277.05% | 311.51% | 829.94% |
| SG&A Expenses | 2.87% | -12.32% | -27.37% | -39.91% | -46.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -23.61% | -50.67% | -60.05% | -42.02% | -36.86% |
| Total Operating Expenses | 0.84% | -10.42% | -31.87% | -41.75% | -47.62% |
| Operating Income | 89.48% | 86.78% | 80.72% | 75.52% | 72.25% |
| Income Before Tax | 71.75% | 70.21% | 81.66% | 76.07% | 76.66% |
| Income Tax Expenses | 121.60% | 62.96% | -71.76% | -168.87% | 98.25% |
| Earnings from Continuing Operations | 71.43% | 70.25% | 81.80% | 76.22% | 74.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.43% | 70.25% | 81.80% | 76.22% | 74.67% |
| EBIT | 89.48% | 86.78% | 80.72% | 75.52% | 72.25% |
| EBITDA | 110.85% | 99.67% | 88.62% | 81.96% | 77.90% |
| EPS Basic | 72.58% | 73.59% | 90.34% | 88.12% | 88.20% |
| Normalized Basic EPS | 80.66% | 79.08% | 81.71% | 81.69% | 85.33% |
| EPS Diluted | 72.58% | 73.59% | 90.34% | 88.12% | 88.20% |
| Normalized Diluted EPS | 80.66% | 79.08% | 81.71% | 81.69% | 85.33% |
| Average Basic Shares Outstanding | 6.26% | 10.67% | 27.35% | 51.85% | 92.66% |
| Average Diluted Shares Outstanding | 6.26% | 10.67% | 27.35% | 51.85% | 92.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |